Tlr11 Antibody

What is TLR11 and what is its primary function in the immune system?

TLR11 is a pattern recognition receptor that participates in the innate immune response to microbial agents. It functions through the MyD88 and TRAF6 signaling pathway, ultimately leading to NF-kappa-B activation, cytokine secretion, and inflammatory response . TLR11 recognizes two distinct protein pathogen-associated molecular patterns (PAMPs): flagellin from bacteria such as Salmonella and E. coli, and profilin-like protein from the parasite Toxoplasma gondii . This dual recognition capability enables TLR11 to contribute to host defense against both bacterial and parasitic infections by initiating appropriate immune responses.

Where is TLR11 predominantly expressed in mammals?

TLR11 exhibits a distinctive tissue expression pattern that differs from other Toll-like receptors. It is highly expressed in the liver, bladder, and kidney tissues, while showing relatively weak expression in the spleen . This expression pattern correlates with its functional role in recognizing uropathogenic bacteria, particularly in the urinary tract, suggesting an evolutionary adaptation for defending against urinary infections. When designing experiments targeting TLR11, researchers should consider this tissue-specific expression profile when selecting appropriate cell lines or primary cells.

What types of TLR11 antibodies are available for research?

Several types of TLR11 antibodies are available for research applications:

• Polyclonal antibodies: Most commonly available TLR11 antibodies are rabbit polyclonal, such as ab21274 from Abcam and ABIN500942 , which target different epitopes within the TLR11 protein.

• Region-specific antibodies: Researchers can select antibodies targeting specific regions of TLR11:

  • C-terminal targeting antibodies (like ABIN500942)

  • Antibodies raised against synthetic peptides within mouse TLR11

  • Antibodies targeting specific amino acid regions (e.g., AA 911-926, AA 430-460)

• Conjugated antibodies: Some TLR11 antibodies are available with fluorescent conjugates (such as FITC) for flow cytometry and fluorescence microscopy applications .

The selection of an appropriate antibody depends on the specific experimental application and the species being studied, with most commercial antibodies optimized for mouse TLR11 detection.

How do TLR11 interactions with flagellin and profilin differ mechanistically?

TLR11 exhibits distinct interaction mechanisms with its two protein ligands (flagellin and profilin). Research has demonstrated that:

• Different receptor domains are utilized: TLR11 employs different structural regions to bind flagellin versus profilin-like protein from T. gondii .

• pH dependency varies: The binding interactions show differential sensitivity to pH conditions, suggesting distinct biochemical requirements for each ligand-receptor interaction .

• Receptor ectodomain cleavage affects binding differently: Studies show that ectodomain cleavage of TLR11 impacts profilin binding but appears to have different effects on flagellin recognition . Specifically, when TLR11 is cleaved, it fails to bind to T. gondii profilin (TPRF), suggesting that both the N- and C-terminal regions of TLR11 are critical for interaction with this ligand .

When designing experiments to study these interactions, researchers should consider these differences and adjust experimental conditions accordingly. For instance, buffer pH should be carefully controlled when comparing TLR11 binding to different ligands.

What are the key considerations when optimizing Western blot protocols for TLR11 detection?

Optimizing Western blot for TLR11 detection requires attention to several technical factors:

• Antibody selection: Use antibodies validated for Western blot applications, such as ab21274 or ABIN500942 .

• Sample preparation: Cell lysates from RAW264.7 macrophages have been successfully used to detect TLR11 by Western blot . When working with tissue samples, prioritize liver, kidney, and bladder tissues where TLR11 is highly expressed .

• Expected molecular weight: The predicted band size for TLR11 is approximately 105 kDa . Be aware of potential post-translational modifications that might affect migration patterns.

• Antibody concentration titration: Empirical determination of optimal antibody concentration is recommended. For example, ab21274 has been tested at both 0.5 μg/ml and 1 μg/ml concentrations in Western blot applications .

• Controls: Include positive controls (RAW264.7 cell lysates) and negative controls (samples from TLR11 knockout mice if available) to validate specificity.

• Detection method: Standard chemiluminescence detection methods are suitable for TLR11 Western blots.

How can researchers distinguish between TLR11-dependent and TLR11-independent immune responses?

Distinguishing between TLR11-dependent and TLR11-independent immune responses requires careful experimental design:

• Genetic approaches:

  • Compare responses in wild-type versus TLR11-deficient mice

  • Use compound knockout models (e.g., TLR11xCasp1/11-/- mice) to identify redundant or compensatory mechanisms

• Cytokine profiling:

  • Measure IL-12 production, which is strongly associated with TLR11-dependent responses to T. gondii

  • Assess IL-18 levels, which become particularly important in TLR11-independent, inflammasome-dependent responses

  • Monitor IFN-γ production from CD4+ T cells as a downstream readout of both pathways

• Time-course experiments:

  • TLR11-dependent responses typically occur earlier during infection

  • TLR11-independent, inflammasome-dependent responses may become more prominent at later stages, particularly in TLR11-deficient animals

Research has demonstrated that in the absence of TLR11, inflammasome activation and IL-18 production become critical for host immunity against T. gondii . This compensatory mechanism highlights the importance of examining multiple immune pathways when studying TLR11 function.

What structural elements of TLR11 are critical for ligand recognition?

TLR11 structural analysis reveals important elements for ligand recognition:

• Extracellular domain composition:

  • Signal sequence: amino acids M1 to S21

  • Extracellular domain: amino acids T22 to S709

  • Contains 26 leucine-rich repeats (LRRs): LRR-NT, LRR 1–24, and LRR-CT

• Critical binding regions:

  • Both N- and C-terminal regions appear necessary for interaction with T. gondii profilin (TPRF)

  • Chimeric receptor studies using TLR11/2 and TLR2/11 have demonstrated that both constructs can bind flagellin (FliC), suggesting a more flexible structural requirement for this interaction

• Ectodomain cleavage:

  • TLR11 undergoes ectodomain cleavage that affects its binding properties

  • The cleaved form of TLR11 fails to bind TPRF, further indicating the importance of intact N- and C-terminal regions for this interaction

For researchers investigating TLR11 structure-function relationships, targeted mutagenesis of specific LRRs can help identify the precise contribution of different receptor domains to ligand recognition.

How does the TLR11-mediated immune response differ from other TLR responses?

TLR11-mediated responses have several distinguishing features compared to other TLR pathways:

• Ligand specificity:

  • TLR11 recognizes protein PAMPs (flagellin and profilin) from evolutionarily distant pathogens

  • Unlike many other TLRs that recognize nucleic acids or lipid-based PAMPs

• Signaling pathway integration:

  • TLR11 signals through MyD88 and TRAF6, leading to NF-κB activation

  • It cooperates with inflammasomes to regulate T helper 1 (TH1) immunity

  • In TLR11-deficient mice, inflammasome-dependent IL-18 production becomes critical for host immunity against T. gondii

• Tissue-specific expression:

  • TLR11's high expression in liver, bladder, and kidney with low expression in spleen contrasts with other TLRs

  • This expression pattern suggests specialized functions in these tissues

• Redundancy mechanisms:

  • Unlike some TLRs that are non-redundant in certain infections, TLR11 deficiency alone does not significantly increase host mortality during T. gondii infection

  • Only when combined with Casp1/11 deficiency does TLR11 loss result in severe susceptibility

Understanding these differences helps researchers interpret experimental results in the broader context of innate immunity and may guide the development of targeted immunomodulatory strategies.

What are the optimal applications for different TLR11 antibodies?

Different TLR11 antibodies are optimized for specific applications, and choosing the appropriate antibody is crucial for experimental success:

• Western blotting (WB):

  • Antibodies like ab21274 have been validated for WB at concentrations of 0.5-1 μg/ml using RAW264.7 cell lysates

  • C-terminal targeting antibodies such as ABIN500942 are also suitable for WB applications

• Immunocytochemistry/Immunofluorescence (ICC/IF):

  • Antibodies like ab21274 have been tested at 2μg/ml for staining TLR11 in RAW264.7 cells

  • ABIN500942 is also recommended for IF applications

• Flow cytometry (FACS):

  • FITC-conjugated antibodies targeting specific amino acid regions (AA 911-926) are available for FACS applications

• Enzyme Immunoassay (EIA)/ELISA:

  • Antibodies like ABIN500942 are suitable for EIA applications

When selecting antibodies, researchers should consider the species reactivity (most TLR11 antibodies are optimized for mouse samples) and the specific region of TLR11 being targeted, particularly when studying interactions with different ligands.

How can researchers effectively study TLR11's role in T. gondii infection models?

To study TLR11's role in T. gondii infection, researchers should consider this methodological approach:

• Mouse model selection:

  • Wild-type mice

  • TLR11-deficient mice

  • Compound knockout models (TLR11xCasp1/11-/-, MyD88-/-)

• Infection protocol:

  • Monitor parasite burden, host survival, and systemic inflammation

  • Assess both acute and chronic phases of infection

• Immune response analysis:

  • Measure IL-12 production (TLR11-dependent pathway)

  • Assess IL-18 levels (inflammasome-dependent pathway)

  • Quantify peritoneal CD4+IFN-γ+ T cells by flow cytometry

  • Analyze both frequency and absolute numbers of CD4+IFN-γ+ T cells at the site of infection

  • Measure IFN-γ production by intracellular cytokine staining

• Comparative analysis:

  • Research has shown that while neither TLR11 nor Casp1/11 alone are essential for host survival during acute toxoplasmosis, combined deficiency results in rapid mortality comparable to MyD88-deficient mice

  • TLR11-deficient mice show elevated IL-18 levels compared to wild-type and TLR11xCasp1/11-/- mice, suggesting compensatory mechanisms

This approach allows for comprehensive assessment of both TLR11-dependent and TLR11-independent mechanisms of immunity against T. gondii.

What are common challenges in detecting TLR11 expression and how can they be overcome?

Researchers frequently encounter these challenges when detecting TLR11:

• Low endogenous expression:

  • Solution: Focus on tissues with known high expression (liver, kidney, bladder)

  • Consider using cell stimulation to upregulate TLR11 expression before detection

• Antibody specificity issues:

  • Solution: Validate antibody specificity using TLR11 knockout controls

  • Confirm results with multiple antibodies targeting different epitopes

• Cross-reactivity with other TLRs:

  • Solution: Use antibodies that target unique regions of TLR11

  • Perform blocking peptide controls to confirm specificity

• Ectodomain cleavage affecting detection:

  • Solution: Be aware that TLR11 undergoes ectodomain cleavage which may affect epitope availability

  • Consider using antibodies targeting both N- and C-terminal regions

• Western blot detection challenges:

  • Solution: Optimize lysis conditions to ensure complete protein extraction

  • The predicted molecular weight of TLR11 is 105 kDa, but post-translational modifications may affect migration patterns

How should researchers interpret conflicting data between TLR11-dependent and inflammasome-dependent immune responses?

When faced with conflicting data regarding TLR11 and inflammasome pathways:

• Consider redundant mechanisms:

  • Research has demonstrated that TLR11 and inflammasomes provide redundant protection against T. gondii

  • In TLR11-deficient mice, inflammasome activation and IL-18 production become critical for host immunity

  • Similarly, in Casp1/11-deficient mice, TLR11-dependent IL-12 production is sufficient for robust TH1 responses

• Examine temporal dynamics:

  • Different pathways may dominate at different stages of infection

  • Take multiple time points during infection (e.g., day 5 and day 8 post-infection)

• Quantify specific readouts:

  • Measure both upstream mediators (IL-12, IL-18) and downstream effectors (IFN-γ)

  • Assess both systemic cytokine levels and local immune responses at infection sites

• Consider genetic background:

  • The high susceptibility of MyD88-deficient mice (which is not observed in TLR11- or Casp1/11-deficient mice) suggests that multiple pathways converge on MyD88-dependent signaling

• Design definitive experiments:

  • Use compound knockout models (e.g., TLR11xCasp1/11-/-) to definitively establish the relationship between pathways

  • Perform adoptive transfer experiments to determine cell-intrinsic versus cell-extrinsic effects

By considering these factors, researchers can better interpret seemingly conflicting data and develop a more comprehensive understanding of how TLR11 contributes to immune responses.

What are promising areas for future TLR11 research?

Several key areas for future TLR11 research include:

• Structural biology:

  • Detailed crystallographic analysis of TLR11 in complex with its ligands

  • Further mapping of the specific LRRs involved in recognizing different ligands

  • Investigation of the structural basis for the differential pH dependency of ligand binding

• Immunotherapeutic applications:

  • Exploration of TLR11 agonists as potential vaccine adjuvants

  • Investigation of targeted TLR11 modulation for enhancing immunity against T. gondii and uropathogenic bacteria

• Species differences:

  • Comparative analysis of TLR11 function across different mammalian species

  • Investigation of compensatory mechanisms in species lacking functional TLR11

• Cooperativity with other PRRs:

  • Further characterization of the interplay between TLR11 and inflammasomes

  • Investigation of potential cooperation between TLR11 and other TLRs or NLRs

• Tissue-specific functions:

  • Detailed analysis of TLR11's role in liver, kidney, and bladder immunity

  • Exploration of tissue-specific signaling pathways downstream of TLR11